Group 1 - Yuheng Pharmaceutical plans to resolve a debt dispute with Qingdao Pusheng Puli Enterprise Management Center regarding the equity transfer payment for Yuheng Biotechnology, which involves a 42.12% stake valued at 117.6 million yuan [1] - Due to Pusheng Puli's failure to pay the agreed amount on time, Yuheng Pharmaceutical initiated legal proceedings in April 2024, which are currently in the execution phase, with no payments received yet [1] - Pusheng Puli intends to transfer 20.64% of its stake in Yuheng Biotechnology to Youpeng Biotechnology (Hainan) Co., Ltd., using the proceeds to settle its debt to Yuheng Pharmaceutical [1] Group 2 - November 4 marks the last conversion day for "Nuitai Convertible Bonds," allowing investors to convert their bonds before market close [1] - After November 4, any unconverted "Nuitai Convertible Bonds" will be forcibly redeemed at a price of 100.36 yuan per bond, potentially leading to losses for investors [1]

Core Viewpoint - The company is addressing a debt dispute related to the equity transfer payment of Guangzhou Yuheng Biotechnology Co., Ltd. through an agreement with Qingdao Pusheng Puli Enterprise Management Center (Limited Partnership) [1] Group 1: Debt Dispute and Legal Proceedings - The lawsuit regarding the equity transfer payment for Yuheng Biotechnology has entered the execution phase, involving multiple complex steps such as equity assessment, judicial auction, transfer, and payment [1] - The process of selling the equity through conventional judicial procedures and recovering the transfer payment is highly uncertain due to difficulties in assessing and pricing the equity [1] Group 2: Equity Transfer - Pusheng Puli intends to transfer its 20.64% stake in Yuheng Biotechnology to Youpeng Biotechnology (Hainan) Co., Ltd., with the proceeds being used to repay its debt to the company [1]

Core Viewpoint - The company is addressing a debt dispute related to the equity transfer payment of Guangzhou Yuheng Biotechnology Co., Ltd. through an agreement with Qingdao Pusheng Puli Enterprise Management Center (Limited Partnership) [1] Group 1: Debt Dispute and Legal Proceedings - The lawsuit regarding the equity transfer payment for Yuheng Biotechnology has entered the execution phase, involving multiple complex steps such as equity assessment, judicial auction, transfer, and payment [1] - The process of selling the equity through conventional judicial procedures and recovering the transfer payment is fraught with significant uncertainty [1] Group 2: Equity Transfer - Pusheng Puli intends to transfer its 20.64% stake in Yuheng Biotechnology to Youpeng Biotechnology (Hainan) Co., Ltd., with the proceeds being used to repay its debt to the company [1]

哈尔滨誉衡药业股份有限公司 关于签署《广州誉衡生物科技有限公司之协议书》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 哈尔滨誉衡药业股份有限公司（以下简称"公司"）拟通过签署《广州誉衡 生物科技有限公司之协议书》（以下简称"《协议书》"）的方式，解决公司与 青岛普晟普利企业管理中心（有限合伙）（以下简称"普晟普利"）关于广州誉 衡生物科技有限公司（以下简称"誉衡生物"）股权转让款的债务纠纷问题，具 体背景、内容、对公司的影响及风险等情况，公告如下： 一、公司将持有的誉衡生物股权出售给普晟普利的基本情况介绍 2023 年 6 月 28 日、2023 年 7 月 14 日，公司召开的第六届董事会第五次会 议及 2023 年第一次临时股东大会先后审议通过了《关于出售持有的广州誉衡生 物科技有限公司全部股权的议案》，同意公司将持有的誉衡生物 42.12%股权转 让给普晟普利。根据公司与普晟普利签署的《股权转让协议》，普晟普利应向公 司支付的股权转让款为 2.4 亿元。具体内容详见公司 2023 年 6 月 29 日披露于《证 券时报》、《中国证券报》及巨潮资 ...

Core Viewpoint - Yuheng Pharmaceutical is a well-known chemical formulation enterprise in China, with strong competitiveness in drug production and agency sales, and a rich product line and professional marketing team [1] Group 1: Business Performance - In Q3 2025, Yuheng Pharmaceutical reported revenue of 1.665 billion yuan, ranking 39th among 110 companies in the industry, while the industry leader, Huadong Medicine, had revenue of 32.664 billion yuan [2] - The net profit for the same period was 248 million yuan, placing the company 30th in the industry, with the top performer, Heng Rui Medicine, achieving a net profit of 5.76 billion yuan [2] Group 2: Financial Ratios - As of Q3 2025, Yuheng Pharmaceutical's debt-to-asset ratio was 28.13%, down from 32.28% year-on-year, which is lower than the industry average of 35.26%, indicating improved debt repayment capability [3] - The gross profit margin for Q3 2025 was 46.42%, down from 53.25% year-on-year, and below the industry average of 57.17%, suggesting a need for improvement in profitability [3] Group 3: Management Team - The chairwoman, Shen Zhenyu, has a rich background and has held various leadership positions, while the general manager, Guo Leifeng, has extensive experience in investment management [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 2.99% to 102,500, while the average number of circulating A-shares held per shareholder increased by 3.08% to 20,400 [5] - The top circulating shareholder, Hong Kong Central Clearing Limited, increased its holdings by 35.136 million shares [5] Group 5: Future Outlook - Tianfeng Securities has adjusted its revenue forecasts for 2025-2027 to 2.364 billion, 2.464 billion, and 2.661 billion yuan, while raising net profit forecasts to 258 million, 282 million, and 318 million yuan for the same period [5] - First Capital Securities expects revenues of 2.437 billion, 2.751 billion, and 3.08 billion yuan, with net profits of 256 million, 291 million, and 328 million yuan for 2025-2027 [6]

Summary of Yuheng Pharmaceutical Conference Call Company Overview - **Company**: Yuheng Pharmaceutical - **Industry**: Pharmaceutical Key Financial Performance - **Q3 Net Profit**: Increased by 87% YoY to 109 million CNY, with a net profit of 244 million CNY for the first nine months, up 32.85% YoY [2][3] - **Non-Recurring Profit**: Q3 non-recurring net profit reached 71.46 million CNY, a 47% increase YoY; cumulative non-recurring net profit for 1-9 months was 178 million CNY, up 24.69% YoY [2][3] - **Return on Equity**: Weighted average return on equity reached 11.93% for the first nine months, showing slight growth [2][3] - **Net Assets**: As of September, net assets attributable to shareholders grew by 10.58% YoY to 2.157 billion CNY [2][3] Product Sales and Growth Drivers - **Sitagliptin Metformin Extended-Release Tablets**: Sales revenue of approximately 25 million CNY with over 200,000 bottles sold in 1-9 months; expected to maintain rapid growth in Q4 and continue to expand in 2026 [2][5] - **New Product Contributions**: Future growth driven by new products like Anbrain Tablets and Sitagliptin Metformin, along with the introduction of new products like Pimecrolimus [6][12] - **甲钴胺 Injection**: Expected to contribute over 15 million CNY in revenue in 2026 [5][13] Strategic Partnerships and Collaborations - **BD Collaborations**: Partnerships with Japanese companies Seikagaku and Eisai for the promotion of Temozolomide and Methylcobalamin injections [5][11] - **Acquisition Strategy**: Company emphasizes acquisitions as a key strategy for growth, with approximately 800 million CNY in cash and a low debt ratio, planning to use a mix of equity payments, acquisition loans, and own funds for future acquisitions [4][10] Market and Competitive Landscape - **Impact of National Procurement**: Participation in the 11th round of national procurement has affected sales, particularly for products like Plavix Sodium Tablets, which accounted for about 7% of total sales [14][17] - **Market Competition**: Anticipation of increased competition in 2026 with four new competitors entering the market, leading to price reductions despite expected volume growth [16][17] Cost Management and Profitability - **Sales Expense Ratio**: Significant decrease in sales expense ratio due to reduced market investment and product price adjustments, now below 25% [4][8] - **Cost Control**: Ongoing efforts to manage operational costs effectively, with a focus on maintaining profitability [4][12] Future Outlook - **Growth Expectations**: Management expresses confidence in achieving stable long-term growth, driven by both existing and new products, while remaining cautious about the impact of non-recurring gains [12][18] - **Market Adaptation**: Company plans to adapt to future procurement policies and market changes to sustain growth [14][17] Additional Insights - **Investment Fund Performance**: Increase in fair value gains from investments, particularly in Base Pharmaceuticals, with future gains dependent on market performance [4][7] - **Focus on External Innovation**: Company prioritizes external collaborations over in-house R&D for innovative drugs, indicating a strategic shift towards partnerships [9][11]

Financial Performance - The company reported a net profit increase in Q3, primarily due to significant non-recurring gains from investments, particularly a substantial rise in the stock price of its invested fund WuXi L.P. [5] - Revenue from the core products, including potassium chloride sustained growth, with sales of the injection of multiple vitamins (12) and other exclusive Chinese medicine varieties showing robust performance [5][6] Product Development and Sales Outlook - The company has signed promotional agreements for new products, including Pemafibrate tablets and Mecobalamin injection, with expected revenue contributions of over 7 million in 2025 and around 15 million in 2026 respectively [3][4] - Sales of the Sitagliptin Metformin sustained-release tablets reached approximately 25 million in the first nine months of 2025, with a sales volume of nearly 200,000 bottles [3][4] Market Strategy and Growth Drivers - Future growth is anticipated from multiple sources, including core products that contribute over 60% of total revenue, and new products like Pemafibrate and Mecobalamin [5][6] - The injection of multiple vitamins (12) has seen over 40% sales growth in 2024, with a projected increase of over 10% by the end of 2025 [4] Cost Management - The sales expense ratio decreased to below 25% by the end of September, attributed to the impact of centralized procurement policies [7] - The company aims to maintain a low sales expense ratio while managing internal marketing effectively [7] Future Plans and M&A Considerations - The company is focused on introducing MNC products domestically, particularly through partnerships with Japanese firms, and is exploring opportunities in differentiated products within its core areas [8][9] - The company has over 100 million in self-owned funds available for potential acquisitions, alongside options for acquisition loans [9] Investment and Shareholder Communication - The company holds a 3.46% stake in Yu Cheng Capital, with significant projects like the Hong Kong-listed Basestone Pharmaceuticals contributing to fair value gains [9] - The company emphasizes ongoing communication with investors and welcomes further engagement [9]

Core Viewpoint - Yuheng Pharmaceutical (002437) announced on October 28 that as of October 20, 2025, the total number of shareholders is expected to be approximately 105,500 [1] Summary by Categories - Company Information - Yuheng Pharmaceutical's total number of shareholders is projected to be around 105,500 by October 20, 2025 [1]

Group 1 - The core viewpoint of the news is that Yuheng Pharmaceutical reported its third-quarter performance, showing a decline in revenue but an increase in net profit and earnings per share [1] Group 2 - For the first three quarters of 2025, the company's revenue was approximately 1.665 billion yuan, a year-on-year decrease of 10.36% [1] - The net profit attributable to shareholders was about 244 million yuan, reflecting a year-on-year increase of 32.85% [1] - The basic earnings per share were 0.1111 yuan, which is a year-on-year increase of 33.05% [1] - As of the report date, the market capitalization of Yuheng Pharmaceutical was 7.2 billion yuan [2]

Financial Performance - The company's revenue for Q3 2025 was CNY 565,496,071.70, a decrease of 11.11% compared to the same period last year[4] - Net profit attributable to shareholders increased by 86.86% to CNY 109,341,035.92 for Q3 2025[4] - The basic earnings per share rose by 78.49% to CNY 0.0498 in Q3 2025[4] - Total operating revenue for the current period is ¥1,664,997,338.49, a decrease of 10.36% from ¥1,857,506,712.57 in the previous period[22] - Net profit for the current period is ¥247,923,573.93, an increase of 29.36% compared to ¥191,786,315.95 in the previous period[23] - Basic earnings per share for the current period is ¥0.1111, up from ¥0.0835 in the previous period[24] Assets and Liabilities - Total assets as of September 30, 2025, reached CNY 3,029,960,091.66, reflecting a 7.25% increase from the end of the previous year[4] - Total assets amount to ¥3,029,960,091.66, an increase from ¥2,825,112,612.64 in the previous period[21] - Total liabilities are ¥852,180,333.41, slightly down from ¥852,260,332.70 in the previous period[21] - The company’s total non-current assets decreased to ¥1,880,921,737.96 from ¥1,947,918,407.46 in the previous period[21] - The company’s total equity increased to ¥2,177,779,758.25 from ¥1,972,852,279.94 in the previous period[21] Cash Flow - Cash flow from operating activities for the year-to-date was CNY 308,264,860.41, an increase of 2.58%[4] - Operating cash inflow for the current period is CNY 1,936,541,711.79, down from CNY 2,184,252,323.73 in the previous period, representing a decrease of approximately 11.3%[25] - Net cash flow from operating activities is CNY 308,264,860.41, slightly up from CNY 300,502,502.62 in the previous period, indicating a growth of about 2.3%[26] - Cash inflow from investment activities significantly increased to CNY 979,014,562.57 from CNY 31,412,568.97, marking a substantial rise of approximately 3020.5%[26] - Net cash flow from investment activities is negative at CNY -328,824,664.41, compared to CNY -4,852,200.48 in the previous period, indicating a worsening situation[26] - Cash inflow from financing activities decreased to CNY 70,000,000.00 from CNY 218,213,750.00, a decline of about 67.9%[26] - Net cash flow from financing activities is CNY -20,260,190.15, an improvement from CNY -537,441,513.66 in the previous period[26] - The ending cash and cash equivalents balance is CNY 438,984,652.89, down from CNY 468,538,477.75 in the previous period, reflecting a decrease of approximately 6.5%[26] - Total cash outflow from operating activities is CNY 1,628,276,851.38, down from CNY 1,883,749,821.11, a reduction of about 13.5%[26] - Cash outflow from investment activities is CNY 1,307,839,226.98, significantly higher than CNY 36,264,769.45 in the previous period, indicating a rise of approximately 3505.5%[26] Expenses - The company experienced a 34.88% reduction in selling expenses, totaling CNY 411,395,500.83, primarily due to decreased market management costs[10] - Total operating costs for the current period are ¥1,463,760,914.56, down 13.24% from ¥1,686,482,833.11 in the previous period[22] - Research and development expenses for the current period are ¥49,714,579.12, a slight increase from ¥48,755,362.80 in the previous period[23] - The company reported a decrease in sales expenses to ¥411,395,500.83 from ¥631,722,798.46 in the previous period, reflecting a cost-cutting strategy[22] Shareholder Information - The total number of common shareholders at the end of the reporting period is 102,544, with no preferred shareholders having restored voting rights[13] - The top shareholder, Shen Zhenyu, holds 4.92% of shares, amounting to 110,490,000 shares, with 82,867,500 shares subject to lock-up[13] Government Support and Recognition - The company received government subsidies amounting to CNY 24,134,568.42, a decrease of 49.92% compared to the previous year[10] - The company received a total of 3.4629 million RMB in subsidies during the reporting period, including 500,000 RMB for project support[16] - The company was awarded the "2025 China CDMO Ranking TOP20" at the CMC-CHINA Pharmaceutical Expo[17] - The company’s subsidiary received recognition as an innovative small and medium-sized enterprise by the Guangdong Provincial Department of Industry and Information Technology[17] Product Development - The company has six products that have obtained drug registration certificates, covering various therapeutic areas[16] - The company’s subsidiary, Harbin Yuheng Pharmaceutical, has passed consistency evaluations for two products in September 2025[16] Governance - The company has canceled the supervisory board, achieving a smooth transition in governance structure[17]